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RECOMMENDATIONS & FUTURE DIRECTIONS 
1. That further front-of-house pill testing, as part of a commitment to harm reduction services, be 
supported in the ACT.  
2. That appropriately sized and signed facilities for front-of-house pill testing be negotiated with all relevant 
stakeholders in a timely manner prior to events.  
3. That Australian state and territory governments engage in discussions with their relevant ACT 
counterparts on the introduction of medical and peer based front of house pill testing services. 
4. That Australian state and territory governments utilise the significant practical and strategic knowledge 
of the STA-SAFE consortium in their deliberations on the introduction of pill testing.  
5. That the federal government take a national leadership role in advancing a mixed-model approach to pill 
testing as a harm reduction service across Australia, where front-of-house testing services are delivered 
on site at music events and festivals, as well as at fixed locations, such as participating public health, drug 
and alcohol and needle and syringe programs. 
6. That all levels of government work together with the STA-SAFE consortium to establish a national pill 
testing evaluation framework, as well as an ongoing public early warning system (EWS) of all drug test 
results. 
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OVERVIEW AND RATIONALE FOR THE PILOT 
INTRODUCTION 
Despite repeated drug related incidents occurring for many years at music festivals across the country, some 
of them fatal, governments of all persuasions have continued to prioritise a punitive supply reduction 
strategy for festivals. More often than not, governments have increased the number of sniffer dogs and 
police presence, despite the lack of evidence for, anecdotal or otherwise, to support the effectiveness of this 
approach in reducing the prevalence of drug use or drug related harms occurring, and some evidence that an 
increased police presence including sniffer dog operations could increase harms (NSW Ombudsman, 2006). 
Even as families, festival goers, promoters, as well as public health and law enforcement officials, were 
becoming more concerned with the continuing drug-related incidents occurring at festivals, governments 
have continued to resist calls for pill testing as a harm reduction intervention. 
Agitation for change has been emerging across the wider community reflected by significant discussion of the 
issues by the media and in particular social media.  
Some political organisations such as the Greens Party and the Reason Party, and some individual members of 
parliaments from all parties, including the Liberal and Labor parties, have called for change that prioritises 
health outcomes over a law and order approach. The impact of strong vocal support from family groups such 
as Family Drug Support and people attending festivals also cannot be underestimated. 
Within this growing push for change, the STA-SAFE consortium was conceived and began its efforts to 
introduce pill testing, as a harm reduction intervention, in Australia – an intervention based on the best 
evidence and experience available internationally, as well as local insight.  
The model developed by the consortium was a front-of-house service with a strong level of medical, health 
and peer representation in both direction and delivery.  
After a number of delayed starts at festivals in Canberra, the STA-SAFE consortium was able to secure the 
strong and publicly announced support of the ACT government, including ACT health and police, the 
University of Canberra (the venue where the GTM festival was being held), and the GTM promoters 
(Cattleyard), for a pilot of pill testing at the 29 April 2018 GTM festival in Canberra. 
The introduction of an officially sanctioned pill testing harm reduction service in Australia has taken over a 
decade of commitment (Camilleri and Caldicott, 2005). 
In conducting the pilot no funds were requested or provided by the ACT government, or any other 
government, for the development or delivery of the service. The pilot was completely self-funded by 
members of the consortium and their supporters along with significant pro-bono assistance provided by legal 
and other professionals. 
VISION 
After reviewing the existing evidence and models of pill testing from around the world, the vision of the STA-
SAFE consortium became very clear: 
To obtain government, landowner and festival promoter support for a sanctioned ‘front-of-house’ 
pill testing program at one of the larger upcoming festivals in the ACT1. 
                                                                
1 “Front of house” pill testing refers to a service that operates for the benefit of patrons at festivals, involves peers as 
equal partners and works co-operatively with all engaged emergency management team stakeholders, including police 
and health services. Back of House testing refers to a service that provides information gathering for law enforcement, 
but may also be available for other engaged emergency management team stakeholders, but not patrons, and the results 
may or may not be displayed for the benefit of patrons at festivals. 
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FRAMEWORK 
Pill testing2 involves using analytical instruments to determine the chemical content of drugs to be consumed 
by people at venues and festivals, as well as other locations, with the purpose of reducing the harms 
associated with consuming those drugs. 
Typically, the person about to consume the drug brings it for testing and is provided with an on-site analysis 
by people trained in the use of the testing equipment. The person is also provided with information about the 
risks of consuming the substances identified, education of harm reduction strategies to mitigate that risk, and 
other support services including health and community service referrals. 
Evidence of the results of pill testing show that it can be a significant and positive intervention. Some people 
decline to use a drug when a chemical analysis shows the dangerous or unexpected compounds contained in 
the pill and when it is presented to them in both a clinical and community service-based manner by peers and 
other experts (Kriener and Schmid, 2002). 
Some research has shown that less than one percent of MDMA users access medical treatment (Global Drug 
Survey, 2017). Further, some existing pill-testing programs offer a range of harm reduction services that 
extend well beyond testing drugs (Benschop, Rabes and Korf, 2002).  These two factors open the possibility of 
expanding and enhancing access to health and welfare services for people attending festivals in Australia. 
This approach mirrors the engagement already seen at needle and syringe programs and drop-in centres 
where people have an opportunity to talk about their drug use and other issues with health and community 
service professionals. 
In the case of pill testing, for many it is their first engagement with these professionals and serves as an 
opportunity to receive information about how to minimise risks and receive specific education about what 
may actually be in the pills they are intending to consume. As a harm reduction service, pill testing, offers the 
unique opportunity to reach a group of primarily young people who do not usually access traditional alcohol 
and other drug (AOD) services. 
One of the consequential outcomes of existing pill-testing regimes around the world has been a consumer-led 
safety movement for the quality of drugs being sold and consumed. For example, test results that have 
shown high levels of impurities in the drugs have been shown to alter the nature of the market and modify 
drug-taking behaviour in Europe (Energy Control, 2011). 
It was also evident to the STA-SAFE consortium that for the pill testing program to be as successful as other 
harm reduction initiatives in Australia, the involvement and inclusion of peer group representatives were 
required as equal partners at all stages of the process. 
As a result, the framework agreed and undertaken by the STA-SAFE consortium to deliver the pill testing 
service involved the preparation of detailed documentation on both the evidence base and the operational 
protocols of the proposed harm reduction service. Concurrently, there was engagement in a series of 
discussions with key ACT government ministers and other relevant stakeholders. 
Accordingly, as the value of the STA-SAFE consortium proposal became more evident to ACT government 
officials, the STA-SAFE engagement approach focused on key ACT government departments, particularly 
health and police, the festival promoters and local AOD agency representatives. 
AIMS 
Pill-testing in some other contexts has primarily been an intelligence gathering exercise for health and law 
enforcement services with communication to the public limited to warnings about ‘dangerous’ substances – 
effectively a ‘need to know’ basis.  This model is often referred to as ‘back of house’. In contrast, the STA-
SAFE model for this pill testing pilot was informed by a harm reduction approach that seeks to empower 
patrons with knowledge about the substances they are taking while also providing important data to those 
tasked by government to deliver harm reduction interventions including targeting supply chains and drug 
dealing.  
  
                                                                
2 Pill testing is also known as drug checking 
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More specifically the overarching aim of the service is to save lives by: 
• Providing the opportunity for people to be informed and consider a range of options before 
determining whether or not to consume an illicit drug; 
• Reducing the number of people potentially requiring an ambulance call out, as well as attending 
hospitals, police holding cells and courts as a result of consuming unknown drugs - which in turn 
delivers a range of individual, family and community based positive outcomes; and 
• Obtaining a range of street samples for detailed testing that allows for community health warnings 
on new compounds and assists law enforcement intelligence on illegal drug manufacturing and 
importations in Australia. 
CURRENT SITUATION 
AUSTRALIAN DRUG USE DATA 
Australia’s illicit drug market is part of a complex global and domestic network of suppliers, traffickers and 
dealers where profits are high and the aggregate risks are low, particularly for those who control these 
networks. Countries like Australia, with a relatively high disposable income and high consumer demand, are 
attractive destinations for a range of illicit drugs. In the past decade the demand for psychoactive substances 
has fuelled significant growth in the manufacture of new synthetic drugs as shown in Figure 1. 
Figure 1: Growth in synthetic drugs globally and selected government responses. 
Source: The expanding universe of synthetic drugs, The Economist May 20th 2017 
 
In Australia, the best population wide data on drug use patterns is the National Household Survey based on 
23,772 respondents who were interviewed in 2016.  Eight and half million (or 43%) of people aged 14 and 
older reported using an illicit drug at some point in their lifetime (AIHW, 2017a: 53). Overall eleven percent of 
people reported they had tried ecstasy at some point in their lives with the number increasing to 19% of 
those aged between 20 and 29. 
The most commonly used illegal drugs in the 12 months prior to the interviews were cannabis (10%), cocaine 
(2.5%), ecstasy (MDMA, 2.2%) and meth/amphetamines (1.4%) (AIHW, 2017a: xi). MDMA use was higher for 
those aged 14-19 years (3%) and 20-29 years (7%). 
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Males and those in their twenties are more likely to report illicit drug use in the previous 12 months. Ecstasy 
tends to be used less frequently than cannabis and meth/amphetamine (AIHW, 2017a: 59) with 51% of 
MDMA users reporting they only used ecstasy once or twice a year. Just under two percent of users reported 
that although they wanted to, they could not stop or cut down on their use of ecstasy (AIHW, 2017a: 60). 
In the 12 months prior to the interviews, half of ecstasy users (51%) used pills or tablets. Another third said 
they used capsules while 1 in 10 (11.6%) used crystal. Those aged under 30 were more likely to use capsules 
than people aged 30 or older (AIHW, 2017a: 66). 
The most common reason that an illicit substance was first used was curiosity (65%), followed by use or offers 
by friends or family (50%) (AIHW, 2017a: Table 5.61); these were the main two reasons for both recent and 
ex-illicit drug users. For those who continue to use, the two most common reasons were ‘to enhance 
experience’, or ‘improve mood or stop feeling unhappy’. Of all the age groups 14-19 years were most likely to 
be influenced by friends and family (AIHW, 2017a: 74). For those who had never used the most common 
reason was ‘not interested’ while only one in three were concerned about legal consequences. 
Twenty-seven percent of recent ecstasy users aged 18 years and over reported high or very high levels of 
psychological distress and 26% reported they had been diagnosed with or treated for a mental illness (AIHW, 
2017a: 95). Thirty-nine percent of respondents believed the most appropriate response for someone found in 
possession of small quantities of ecstasy was referral to treatment or an education program (AIHW, 2017a: 
119). 
ACT DRUG USE DATA 
The ACT has a slightly higher proportion of persons self-reporting recent use of ecstasy3 however the 
estimate is based on a small sample size. Males report higher levels of ecstasy use in the previous 12 months. 
Table 1: Used ecstasy in past 12 months, aged 14 years or older, 2016 (percent) 
Sex NSW Vic Qld WA SA Tas ACT NT Aus. 
Males 2.4 2.5 2.8 3.4 *2.1 *3.1 *3.1 *3.7 2.6 
Females 1.6 2.5 1.5 3.0 *1.5 *1.8 *1.2 *1.3 2.0 
Persons 2.0 2.5 2.2 3.2 1.8 *2.4 2.2 2.6 2.3 
* Estimate has a relative standard error of 25% to 50% and should be used with caution. 
Source: Australian Institute of Health and Welfare 2017b. 
 
More detailed data are publicly available from specific studies of particular groups who use illicit drugs.  
Although these studies are based on small non-random samples, these people have higher levels of 
engagement with the drug throughout the year. Data from the ACT 2017 Ecstasy and Related Drugs Reporting 
System (EDRS) found all of the 100 people interviewed had used some form of ecstasy in the past 6 months 
with the most common form being pills and the least common powder (Butler, 2017). Twenty-nine percent 
reported that ecstasy was their drug of choice. Twenty-eight percent said they used ecstasy weekly or more 
often. 
In the ACT around half of those interviewed reported that availability of pills (51%) and capsules (52%) was 
very easy and between 25 and 29% said purity was high while 14 and 20% said it fluctuates. The majority of 
users said they bought it from friends (53%) followed by dealers (29%). Australian ecstasy pills are amongst 
the most dangerous in the world (Project Know, 2016). 
  
                                                                
3 Ecstasy is a street term for press pills meant to contain MDMA 
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Table 2: Availability and purity of ecstasy in the ACT, 2016-2017, (percent) 
 Pills Capsules Powder MDMA 
crystal/rock 
Current availability (n) (70) (79) (14) (60) 
Very easy 51 52 36 35 
Easy 34 41 43 57 
Difficult 13 6 14 8 
Very difficult  1 1 7 0 
Current purity (n) (69) (77) (14) (61) 
Low 13 16 14 5 
Medium 38 46 64 46 
High 29 25 21 39 
Fluctuates 20 14 0 10 
Source: Australian Drug Trends 2017, Tables 8-11.  
 
The majority of ACT EDRS participants in 2017 were poly drug users. Three-quarters reported that the last 
time they used ecstasy or other psychostimulants, they had used other drugs at the same time. The drugs 
most commonly used in combination with psychostimulants were ecstasy, tobacco, alcohol, and cannabis. Of 
those who reported having experienced a stimulant overdose in the past 12 months in 2017 (21%), just under 
half (46%) attributed it to ecstasy. 
When asked about their last location of use ACT respondents in 2017 reported the two most common places 
were nightclubs (39%) and live music events (12%); eight percent said their last use was at a ‘rave’.4 Twenty-
four percent said they had at some time in their life purchased a drug online, while 19 percent said they had 
purchased the drug online in the past year. 
OPERATIONAL REVIEW 
The purpose of the pilot was to effectively test a ‘proof of concept’. At the outset, many questions required 
answers within the Australian context: 
• Was it possible to actually deliver an on-site ‘front of house’ chemical testing program at a festival in 
Australia?  
• How efficacious was the chemical testing?  
• Would patrons use the facility?   
• Would law enforcement be able to operate in a way that allowed them to undertake their duties but 
also to allow pill testers to effectively operate the facility?  
• Was it possible to provide brief intervention AOD counselling and referrals to patrons?  
• Was there a capacity to test orphan samples to assist on site emergency services including health 
and law enforcement?  
• Was it possible to collect operational data that would assist stakeholders in future planning?  
  
                                                                
4 That is, a multi-day music festival with patrons camping on site. 
ACT GTM Pill Testing Pilot: a Harm Reduction Service  
6 
GOALS 
The key goals of the operational review were to: 
• Assess the operational processes of the service with the view to providing recommendations for 
improvement. 
• Obtain key, de-identified aggregated data on patron profile and experiences. 
• Collect data on the outcome of the testing in regard to substances detected, discarding behaviour of 
patrons and future intended use, and any adverse outcomes, and; 
• Gather feedback from volunteers and stakeholders on their experience. 
DATA COLLECTION STAGES AND ASPECTS FOR FUTURE CONSIDERATION 
Prior to their entry to the harm reduction service individuals were appropriately advised of the conditions of 
the pilot. If they agreed to those conditions, chemical tests and data collection were undertaken. No adverse 
events occurred that were linked to the pill testing service. In overall terms, the pilot demonstrated that: 
i) such an intervention is possible; and  
ii) people were willing to use the services, despite the limitations associated with the timelines, 
physical infrastructure and lack of promotion strategies on-site during the festival. 
There were effectively four stages in the process of implementing the pilot at the event and a final stage of 
collation and reporting of data for the review. Each stage is described below. However, there are important 
aspects of the pilot that were effectively pre-operational that directly affected the operational activities. 
These are discussed before the first stage of the point-of-service delivery. 
PRE-PILOT ACTIVITY 
As the final approval to conduct the pilot was only provided 2 to 3 days before the event, there was very little 
time to test the standard operating procedures for the service. Despite there being extensive overseas 
knowledge of comparable pill testing services and significant experience delivering other harm reduction 
services on site at Australian festivals within the deployed team, concerns remained regarding the limited 
knowledge of the physical working environment, and the extent to which patrons would know and feel ‘safe’ 
enough to use the service.  
As requested by STA-SAFE, the ‘tent’ provided on the day was next to the health tent with a common 
entrance.  It had been designed so that it would not be possible to see if patrons entered the pill testing area 
or health tent.  At the front of the entrance, STA-SAFE were required to have a security guard present. When 
asked for feedback seven patrons said that they found the presence of the guard off-putting.  From a risk 
mitigation perspective, having a guard is probably sensible to assist in the rare event of a person becoming 
aggressive, however perhaps rather than being in a formal uniform they could be dressed more casually so as 
not to deter patrons. Further, once pill testing services at festivals are rolled-out, scaled-up, and 
commonplace, all emergency service stakeholders including security staff will have the opportunity to meet 
in advance for service briefings, providing the opportunity to elect the most suitable security staff member 
for that post.  
On entering the shared ‘health’ entrance, if the patron was seeking the pill testing facility they were directed 
by security staff to turn right and then left down a long corridor (approximately 10m) to the formal entrance 
to the pill testing service (see Diagram 1). The corridor was made of 2m high, stabilised, opaque partition 
walls. STA-SAFE staff had erected a temporary screen visually blocking the formal entrance into the testing 
area and, because of the demand at particular times, this marked the starting point for people queuing to be 
inducted into the testing area.   
There was one known instance of two journalists holding cameras above the 2m partition walls and taking 
photographs of people waiting in the queue. One incident was identified immediately and both STA-SAFE and 
the promoters directed that the photographs be deleted.  The second incident was not identified until 
photographs were printed by some News Corp outlets. STA-SAFE were made aware that at least one of the 
people was identifiable (despite attempts to conceal faces) and had complained to ACT health. Following 
direct negotiations by STA-SAFE with News Corp and the journalists, the photograph was withdrawn as media 
entry by the promoter restricts any photography in health precincts by journalists, and breached Cattleyard’s 
media policy. 
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Diagram 1:  Pill testing area* 
 
 
Once patrons entered the screened area, every patron was greeted by a peer-based harm reduction worker 
and asked to volunteer their phone, which was held in a safe for the duration of their time in the testing area 
to guard against photographs, and video and sound recordings. To our knowledge this was not breached 
inside the tent.  But the issue of queuing outside the entrance due to space constraints inside the tent posed 
a significant potential risk of privacy being breached, although this did not appear to be a major consideration 
for patrons using the service.  In addition, the weather became wet and very cold and patrons were left with 
no cover in the corridor when queuing. In feedback on service improvement fourteen patrons indicated that 
more space was required.   
STAGE 1 
Prior to the testing patrons were assessed for eligibility and advised of the safety conditions of entry. The 
conditions are provided in Appendix 1 & Appendix 2.  These were printed and laminated onto large sheets 
and hung outside in the entrance and then inside the induction area where eligibility assessment took place. 
A key condition that had been identified by police regarded possession of quantities of drugs that were legally 
‘deemed’ to be of trafficable quantities. Patrons were advised that if they produced such amounts of drugs 
they would be refused service.  Nobody was refused service for this reason however it is not known if on 
reading these conditions anyone in the queue outside left prior to assessment. 
Although supply level testing did not occur during the pilot the law in this area is complex. If MDMA is taken 
as an example, then the level is around 10g and no-one exceeded this weight. For other substances the 
supply threshold can be much lower. For example, for fentanyl it is around 7.5mg. A situation could arise 
where the weighing and testing reveals a trafficable quantity. Although this did not happen at the pilot it 
could in future, detailed protocols for dealing with this situation need to be further developed in conjunction 
with law enforcement. 
  
ACT GTM Pill Testing Pilot: a Harm Reduction Service  
8 
Another key condition identified by legal and insurance advisors was the need for a waiver form to be signed 
by all patrons.  The wording of the form was drafted with input from a medical clinician and from a pro-bono 
lawyer who assisted in this task. A copy of the form is provided in Appendix 3. The form and its contents were 
explained, and all patrons had to sign it prior to entering the testing area. Signed forms were locked away 
immediately in a safety box and later transported to HRA offices for secure keeping.  Legal advice indicates 
that the waivers need to be securely stored for seven years and then destroyed. Of those who entered the 
assessment area no-one refused to sign a waiver and leave at this point. 
As part of assessing a patron for eligibility, a peer-based harm reduction worker asked a few questions and 
undertook a visual assessment to make sure the patron was not intoxicated and therefore unable to provide 
consent in any meaningful way. On two occasions patrons were refused entry due to intoxication (one based 
on the visual signs of intoxication, namely pupil dilation and bruxism, and the other based on their inability to 
correctly reference the date).  On 11 occasions the harm reduction worker sought a second opinion as 
to whether the patron presenting had the capacity to sign a waiver (including if they appeared intoxicated 
from alcohol or said they were intoxicated with alcohol) and requested the on-site medical clinician to make a 
further assessment. In total 129 people were assessed (this included police/on-ground health staff who 
brought two orphan samples for testing) and the two people who were turned away. 
The stage 1 induction area of the tent was not covered due to the limited space inside the actual tent being 
required for the chemical testing equipment and the brief intervention area.  This was less than ideal with 
rain and increasing cold. During the 12-hour period 3.6 millilitres of rain fell and there were some localised 
thunderstorms.  The temperature dropped to 2.9C.  This again highlighted the need for more covered space 
and depending on the season and location, heating may need to be factored into local planning. 
Accessing the lockable safe after the testing was completed also created some time delays, particularly when 
groups entered the stage 1 area for eligibility assessment. It became evident that on leaving many patrons 
had forgotten they had ‘stored’ their phones in the safe and had to be reminded to collect them.  Designing 
the layout for future services will need to take this into account particularly if numbers accessing the service 
are significantly higher or the exit point is designed to be separate from the induction point. Consideration of 
whether phones need to be ‘confiscated’ on entry should be reviewed on a case by case basis. 
A key issue going forward is how to deal with groups.  There were in total 39 groups (excluding ineligible and 
orphan samples) with 98 people (see Diagram 2). Groups ranged from 2 to 5. There were 27 patrons (22 
percent) who came on their own and a further 46 came in groups of 2 (36 percent). Thirty-nine were in 
groups of 3 (31 percent), eight in groups of 4 and five in groups of 5.  
Diagram 2: Number of groups and individuals who entered the service 
 
Source: HRA STA-SAFE Eligibility Data File, 2018, N=125 
 
125 individual 
presentations
Group of 1 (27 
people)
23 groups of 2 (46 
people)
13 groups of 3 (39 
people)
2 groups of 4 (8 people)
1 group of 5 (5 people)
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Figure 2 shows when patrons accessed the service. The event started at 11.00am and there were three 
individuals who accessed the service in the first hour. Most of the activity was concentrated in two peaks: 
1:00pm-3.00pm and 5:00pm-7.00pm.  There was a noticeable drop-off around 4.00pm which was when the 
weather changed; whether this is causally related cannot be determined. In the last two hours of the service 
10 people were assessed as eligible. Effectively there were patrons coming through every hour. 
Figure 2: Percent of people accessing the facility by hour of day 
 
 
Because of the space constraints a decision was made that all members of a group could enter if they were 
assessed as eligible and signed the waivers, even though they may not have a sample for testing. These 
people were ‘exposed’ to what occurred during the testing and analysis process however counselling was 
limited to only those people who provided a sample. Data collection was restricted to this sub-group of 83. 
Two issues that would provide useful information to inform future operations are a) the time delay between 
eligibility assessment and testing and b) how many people in the ‘groups’ had a sample tested.  From the way 
the data were collected it was not possible to work out who provided samples and hence allow for matching 
of groups to the test results.  What is evident is that in a number of groups, more than one patron had drugs 
for testing.  
Given that the data from both the national household survey and the EDRS indicates that many young people 
are influenced in their drug taking by their family and friends, and that they often source drugs from friends, 
not engaging those people in the group who didn’t provide a sample in a brief harm reduction intervention is 
potentially a missed opportunity and needs to be carefully considered in the future.  It is also reasonable to 
assume that some (if not all) of the ‘group members’ are likely to consume drugs even though they 
themselves are not presenting any drugs for testing.  It should be possible to design a protocol that identifies 
this group and both counsels and collects data from them.   
STAGE 2 
Prior to the testing the patron with the drugs was asked a short pre-test set of questions (see Appendix 4 for 
the HRA pre-test data collection sheet). A unique identifier was allocated to the patron at this point that was 
then used to link to their test results and their responses to the post-test collection sheet. This enabled the 
three pieces of data to be linked anonymously. In regard to the pre-test data collection, 84 patrons 
responded.  However, this was because two patrons in the first group to enter the site were interviewed but 
only one of them presented drugs for testing.  
An important innovation, not previously deployed to the knowledge of the STA-SAFE team, was a ‘catch-and-
release’ system design to track any medical outcomes of those having their drugs tested. The patron who was 
handling the drugs was given a hospital identification (ID) wristband with the tested sample’s unique 
identifier number written on it. The wristbands were of soft vinyl dual-laminate material with tamper 
resistant clips in orange colours. Patrons were advised that they could discard the wristband or store it in 
their pocket or bag, however if they wore it and had an adverse reaction later on, the ID would inform the 
ambulance or hospital that they wanted their test results to be accessed to assist in treatment. 
ACT GTM Pill Testing Pilot: a Harm Reduction Service  
10 
Overwhelmingly, patrons responded positively and many choose to keep them in their pockets. None of the 
wrist band were rejected; it is not known if they were later thrown away. 
The ACT hospitals and ambulance staff were advised of the wristbands and did not report on any patrons 
with wristbands presenting at hospitals or requiring ambulance services during or immediately after the 
festival. ACT ambulance (ACTAS) were able to provide some basic data on presentations to this festival.  In 
2018 there were 85 presentations to the first aid provider and ACTAS. This does not include presentations to 
the additional support services provided by Red Frogs and Headspace.  On these, 20 came directly to ACTAS 
and the majority were for intoxication. ACTAS reported the intoxication as a result of either alcohol or MDMA 
however this relies on their professional judgement and self-reports from patrons. Three patrons were 
transported to hospital and two were for intoxication and the third was not drug related; ACT health advised 
neither of the two intoxicated patrons had undertaken pill testing.  ACT health were unable to provide 
information on these patrons once they entered the hospital environment.  Data from ACTAS indicated there 
were 30 presentations to ACTAS in 2016 and 34 in 2017 as compared to 20 in 2018.  
In the pill testing area, once the patron presented the drugs onto a sheet the chemist proceeded to scrape off 
a portion of the drug for testing purposes. Once submitted, no product, or part of product is ever returned to 
the submitter. At this point the chemist made a technical decision as to whether there was a sufficient 
amount to undertake meaningful tests. Once the test was complete the drugs were disposed of in a locked 
bin that contained bleach. At the end of the evening the bins were appropriately disposed of as chemical 
waste under the supervision of qualified chemists. 
The original intention of STA-SAFE had been to hand the samples across to police for further testing, partly to 
validate the in-field tests with further laboratory testing, as well as to identify individual drug profiles, 
provenance and inform intelligence on illicit drug markets.  However, for the purposes of the pilot, ACT Police 
advised that it was best for them not to be formally involved in the actual testing of the drugs. Nonetheless, 
as supply reduction is part of an overall harm minimisation approach, it should be considered in future 
services. Collecting samples across festivals and over time for more detailed analysis has the potential to 
improve intelligence holdings in a relatively cost-effective manner.  
In total 85 ‘samples’ were provided but two were deemed to not be of sufficient amount for testing. Also two 
of the 85 samples were ‘orphan’ samples; one brought by law enforcement and one from on-ground health 
staff.  They are included in the analysis of the test results but are not included when analysing patron 
responses. The effective usable number of test results was 83. 
Figure 2 showed the flow of data in terms of the total number of people eligible to enter the testing area by 
hour. Figure 3 shows the volume of testing over the 12-hour period. It should be possible to measure elapsed 
time between entry and testing to determine operationally if the concentration of people had an effect on 
the length of time to undertake the tests. It was not possible to assess this in this pilot but it may provide 
important data for managing the flow of groups through the service in the future.  
Figure 3: Chemical tests conducted over the 10-hour period, n=83 
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STAGE 3 
While patrons were waiting for the results they were directed to a brief Intervention with a peer-based AOD 
counsellor and asked eight questions (see Appendix 5). Twelve people at this point declined to answer the 
questions although three did provide open-ended feedback on the service. This effectively reduced the post 
test data to 75 patrons. The tent size meant that some groups were waiting for test results, some people 
were being counselled and others were answering questions all in the close confines of a three by six metre 
tent. None of this was ideal as ‘conversations’ could be overheard and could have had a range of unknown 
effects on patrons. A 6 x 6m space is the ideal minimum-sized space for conducting a front-of-house pill 
testing service.  
STAGE 4 
When the chemical testing of the drugs was completed the results appeared on a screen attached to the 
testing equipment. Using the unique identifier number, the patron was identified and called to the table with 
the drug testing equipment. At this point a chemist and the medical clinician explained what the results were 
to the patron (and others if a group). Due to the constrained space, others, not party to this particular 
discussion, could overhear what was being said.  Although there did not appear to be any concerns, and the 
vast majority of people expressed an understanding of the physical conditions and the delays, the unintended 
consequences of these factors cannot be measured.  
For the purposes of classifying and reporting the result, The STA-SAFE team borrowed the same front-facing 
system used by ChEck IT! In Austria (European Monitoring Centre for Drugs and Drug Addiction, 2018).  ChEck 
IT! is one of the world’s most highly regarded pill testing services, based in Vienna. Test results were assigned 
to one of three different colours (see Diagram 3). All ‘red’ results and some ‘yellow’ and ‘white’ results were 
displayed for all patrons, on similarly coloured pieces of paper, pinned to a notice board to alert patrons of 
what may be circulating around the festival. 
Diagram 3: Classification and reporting of detected substances 
WHITE: Where a substance was analysed, and was the same as what the patron anticipated that it 
might be 
YELLOW: Where a substance was analysed, and there was a significant disparity between the result 
and what the patron anticipated that it was 
RED: Where a substance was analysed, and revealed the presence of a substance known to be 
associated with increased harm / multiple overdoses/ death 
Where a substance was analysed and returned an ambivalent result, or functional groups 
known to be associated with significant harm 
 
It was obvious that patrons did look at the board as they waited and there were discussions around what was 
being ‘discovered’.  One of the patrons responding to the open-ended questions suggested that a printout of 
the tests should be provided to take away and another patron suggested that photographs of the substances 
should be pinned to the board so that patrons could more easily identify different types.  The experience on 
the night suggested that photographs would not be helpful, as the vast majority of samples looked the same; 
further, take away print outs may be used outside the testing facility as drug quality ‘endorsements’; and, as 
discussed later in the report, the results are complex and should not be disseminated without a chemist, 
clinician, and harm reduction worker to explain the substances being ‘identified’.  
Patrons were advised of the amnesty bin in which they could discard their drugs should they choose to do so.  
It was a requirement of the police that the bins contain bleach so all the discarded drugs were immediately 
rendered inert. It was intended that the bin be placed in a discreet location with a person allocated to 
‘observe’ and record the number discarded.  There was simply no room in the tent to implement this model. 
There was also considerable nervousness about the perceived ‘risks’ around the bin so it was placed next to 
the chemist and medical clinician. However, this meant that discarding anything become a highly visible act. 
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As a result, only five patrons were observed discarding their drugs by STA-SAFE staff and this was early in the 
day. It should be noted that at the end of the event, numerous discards were seen in the vicinity of the 
medical precinct, but it is not certain whether this was a reflection on patron uncertainty regarding the 
amnesty bin. This part of the process needs to be carefully reviewed for any future service including whether 
immediately destroying the drugs is a sensible approach if further analysis of the drugs at a later stage might 
assist in signature profiling. 
STAGE 5 
The final stage of the process involved the collection of all the various data collection materials which could 
then be compiled and analysed after the festival. 
Due to the short time frame around approvals of the pilot and the potential risks of complicating the process 
with technology, the data collection was a manual process that later required data entry.  Although this was 
manageable given the numbers, any future service design should consider whether the data collection could 
occur on a hand-held device.  This would improve efficiency and confidentiality, although different protocols 
would be required to manage confidentiality and data security.  However, engaging with patrons with a short 
interview/conversation may put some of them more at ease as well as sending a message that what they 
have to say is important. Open-ended comments often provide useful material to inform practice and the 
extent to which individuals are prepared to type in such data needs to be assessed. 
Producing a datasheet of useable test results was time-consuming as the equipment produced an individual 
PDF file for each test.  It would be more effective if the key data could be outputted to a spreadsheet for 
merging with the other data. However, the PDF files do contain important information in terms of the profile 
of the compounds that can be critical for interpreting results.  In particular, the spectra can be retained and 
later matched to other spectra as they become available. This is important for building the spectra libraries 
globally to assist in drug identification and the development of early warning system capacity. 
Bruker have advised that it is possible to produce such a spreadsheet but this needs to be programmed prior 
to the event.  As the machine was collected in Sydney only two days before the festival the primary 
operational focus was on ensuring that the team were confident in how to conduct the tests, rather than on 
extracting data for later analysis.  This highlights that timeframes between approval for the pilot and the 
delivery had unintended consequences that will need to be mitigated in the future. Any future service needs 
to establish how the data are stored in the Bruker machine and then develop the protocols for transferring 
and merging with the patron data for future analysis. Further discussion on the testing is provided below. 
Although the allocation of the identity numbers worked well it was not entirely straightforward and needs to 
be thought through if a similar process of data collection is envisaged for future services. There were three 
cases where the identity numbers were not entirely clear which required a manual process of checking time 
data as well as some other validation data to determine the correct identity numbers. The key issue for the 
future is to ensure that the identity number on the eligibility and the data collection sheets is also the same 
one assigned to the tests; whether the process remains manual or on hand held devices the process needs to 
be factored in early. 
DRUG TESTING 
The drug testing was undertaken by Fourier-transform infrared spectroscopy (FTIR) using an ALPHA II 
machine supplied on loan by the Bruker Corporation5.This is the technology used by We Are The Loop in the 
UK, and the drug consumption rooms in British Columbia.  In reviewing the most common methods for 
testing illicit drugs Harper, Powell, and Pijl concluded that ‘the best methods for point-of-care drug testing 
are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry 
is the current gold standard in forensic drug analysis’ (2017:1).  The cost and technical skill make it more 
challenging to implement mass spectrometry in a point of care environment like pill testing at a music 
festival.  
Infrared spectroscopy (IR) is a highly discriminatory method and Harper, Powell and Pijl (2017:6) conclude 
that ‘when reference spectra are available, most compounds can be unambiguously identified based on their 
IR spectra…it requires only a very small sample size in the range of milligrams or less. Additionally, samples 
                                                                
5 See Monti (2007) for a discussion FTIR-ATR spectroscopy. 
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can be studied in virtually any physical state…’. The World Health Organisation has stated that ‘infrared 
spectrum is not usually greatly affected by the presence of small quantities of impurities in the substance 
tested’ (WHO, 1997). Interference from moisture can occur but as the samples at the festival were being 
tested immediately this was regarded as a low risk. Importantly, samples required little preparation, so this 
eliminates ‘the possibility of sample contamination during sample preparation’ (Monit, 2007).  
IR is a presumptive test that is able to quickly identify compounds by comparing the spectrum of the 
substances with known spectra in a library/ies. Every compound has a unique spectrum – the key issue is 
whether the measured spectrum has been documented in the library. Where compound spectra are 
contained within the libraries, the IR technique also gives a score out of 1000 that rates the quality of the 
match to the measured spectrum. This information can be used to give a qualitative indication of purity. 
A key issue is that if there is no spectrum documented then the FTIR will automatically identify the closest 
match, hence low hit scores can be meaningless. As new synthetic drugs are constantly being produced it is 
critically important that there be on-going rapid testing to identify and then document these newly 
discovered ‘unknown’ compounds so that they can be added to the spectra libraries.  Figure 4 shows the 
significant increase in the identification of new synthetic drugs as a result of forensic testing of samples. Pill 
testing has an important part to play in this documentation.   
Figure 4: Increasing numbers of synthetic compounds being documented 
 
Source: European Monitoring Centre for Drugs and Drug Addiction, 2017 
An example of a test report is provided in Figure 5. Each compound is assessed against the full range of 
libraries.  The FTIR-Spectra uses the Attenuated Total Reflectance (ATR) technique and accesses the nine 
most up-to-date spectral libraries against the Query Spectrum of the substance being tested. Bruker reports 
that ‘comprehensive spectral data from the following compound classes included: polymers, monomers, 
additives, plasticizer, fillers, building materials, cosmetics, excipients, organic and inorganic chemicals, 
biochemicals, fibres, proteins, fatty acids, lipids, ingredients, natural products, silicon containing compounds, 
solvents, pesticides, pollutants, semiconductors, dyes, paints, coatings, food, food additives, minerals, 
lubricants, surfactants, kidney stones, pharmaceuticals, and drugs’. The library includes the Tictac Drug 
Library which is commonly used by healthcare and law enforcement as well as the pharmaceutical industry 
(TicTac Communications Ltd, 2015). 
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The ALPHA II machine reports a rank ordering of the top three library compound matches to the query 
spectrum along with a score or measure of the quality of the match. This measure ranges from 0 to 1000. The 
closer the number is to 1000 the better the match between query and library spectra and the more likely the 
substance being tested is correctly identified. Work conducted in preparation for the pilot showed that pure 
substances typically gave high match scores of over 750/1000. At the present time there are no national 
standards for Australia on the most appropriate matching criteria for FTIR unlike mass spectrometry where 
there are agreed analytical cut-offs (Makkai, 2000).  In mass spectrometry the established cut-off level varies 
by drug type and importantly Australia has different cut-off levels from other countries depending on the 
drug type. 
PROCESS 
There were a range of forms in which substances were submitted – there were 41 capsules, 25 pills, 10 in 
powder form and six were crystals (and one unclassified).  There was also a range in the weights from 45 to 
1107 mg. As already mentioned two presentations were of such a small weight they were deemed unusable 
resulting in 83 useable samples for testing.  
When the substance is submitted, it is weighed (gross weight) and photographed then a small sample is 
obtained from the pill, capsule or powder. This is placed in scientific weighing paper and then transferred to 
the FTIR machine for spectrum measurement. A background spectrum is acquired immediately before each 
sample spectrum to ensure the data acquired relates to the sample submitted. The query spectrum is then 
matched to the library spectra and a ranked list of scored matches is produced that aims to identify the major 
component. Further analysis of the query spectrum is theoretically possible using subtraction of the major 
component and re-matching to the library, or by performing a regression analysis to obtain the best match to 
a user specified number of components. During the pilot, hardware issues did not allow for this additional 
analysis of minor components. However, this could be achieved in future with only small changes to testing 
methods and time required. Alternatively, retained spectra could be re-analysed after the event.  
An example of what can be provided from FTIR analysis is shown in Figure 5 for sample GTM001 presented as 
MDMA. This identifies MDMA as a component with a low hit quality score (359) relative to that typically 
obtain for pure substances (>750). The analysis also suggests alternative matches to MDEA and safrole of 
lower hit quality score. The sample and library spectra for these matches are shown in Figure 6. Following the 
pilot, a mixture analysis was conducted on the sample spectrum to provide further information about minor 
components and from this a qualitative estimate of sample composition. This mixture analysis identified 
dimethyl sulfone as a likely component as shown in Figures 7 and 8. Dimethyl sulfone is a common filler or 
cutting agent and is generally considered non-hazardous. As noted, hardware problems precluded the use of 
mixture analysis on the day. If mixture analysis is to be undertaken on site in the future, then further 
technical work is required. 
The FTIR analysis is shown in Figure 9 for sample GTM004 that was presented as MDMA. This identifies 
MDMA as a component with a high hit quality score (839) similar to that typically obtain for pure substances 
(>750). The sample and library spectra for these matches are shown in Figure 10. Following the pilot, mixture 
analysis of this sample spectrum did not identify a second significant component. 
In several cases the FTIR analysis uncovered unexpected components. The GTM062 sample presented as 
‘ketamine’ was identified as the antihistamine drug triprolidine with moderately high hit quality score as 
shown in Figures 11 and 12. The GTM074 presented as ‘speed’ was identified as the cathinone drug N-
ethylpentylone with a high hit quality score as shown in Figures 13 and 14. 
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Figure 5: Example of a single component analysis of sample GTM001 presented as ‘MDMA’ that indicates 
MDMA as a component with low score with other ranked matches MDEA and safrole. 
 
 
 
Figure 6: Example of a single component analysis of sample GTM001 showing the IR spectrum of the 
sample (red) and overlaid IR spectra for MDMA (blue), MDEA (pink) and safrole (green). 
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Figure 7: Example of a mixture analysis of sample GTM001 conducted after the pilot showing dimethyl 
sulfone (blue) as a second component of the sample (red). Dimethyl sulfone is a common filler or cutting 
agent. It is considered non-hazardous. 
 
Figure 8: Example of a mixture analysis of sample GTM001 conducted after the pilot showing the sample 
spectrum (red), the composite spectrum derived from MDMA and dimethyl sulfone (blue) and the residual 
spectrum (green).  
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Figure 9: Example of a single component analysis of sample GTM004 presented as ‘MDMA’ that indicates 
MDMA as a component with high score with other ranked matches MDEA of low score. Subsequent 
mixture analysis did not identify a second significant component. 
 
Figure 10: Example of a single component analysis of sample GTM004 showing the sample (red) and 
overlaid IR spectra for MDMA (blue), MDEA (pink and green). 
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Figure 11: Example of a single component analysis of sample GTM062 presented as ‘ketamine’ that 
indicates triprolidine as a component with moderately high score, with other ranked matches ketamine 
and doracryl brilliant red as low score. Subsequent major component (triprolidine) spectrum subtraction 
and re-matching identified ketamine as a minor component. Triprolidine is an antihistamine drug. 
 
Figure 12: Example of a single component analysis of sample GTM062 showing the sample (red) and 
overlaid IR spectra for triprolidine (blue), ketamine (pink) and doracryl brilliant red (green). Note the 
absence of the strong diagnostic peak at 1700 cm-1 in the sample spectrum (red) that is clearly present in 
the ketamine spectrum (pink). 
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Figure 13: Example of a single component analysis of sample GTM072 presented as ‘speed’ that indicates 
N-ethylpentylone as a component with high score with other ranked matches pentylone and topanol M as 
low score. Subsequent mixture analysis did not identify a second significant component. N-Ethylpentylone 
is a cathinone drug that has been associated with fatalities and mass casualty events in other jurisdictions. 
 
 
Figure 14: Example of a single component analysis of sample GTM072 showing the sample (red) and 
overlaid IR spectra for N-ethylpentylone (blue), pentylone (pink) and topanol M (green). 
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RESULTS 
As mentioned earlier, for each substance the machine calculates the top three compounds regardless of how 
poor the fit is to the spectra library. Of the 83 compounds identified as the top match, the intensity score 
ranged from 268 to 936; while for the second identified compound the intensity score ranged from 199 to 
904 and for the third top ranked compound the score ranged from 154 to 817.  Figure 15 shows the intensity 
measures grouped into quartiles or intervals of 250.  It demonstrates the quality of spectrum matches 
declines noticeably from the first to third matched compound. The distributions highlight that compound 1 
(the top match identified) is concentrated at the top end of the hit quality scale while compounds 2 and 3 are 
more likely to be distributed towards the lower end of the hit quality scale.   
Figure 15: Hit quality score distribution of top three compounds identified (n=83) 
 
 
Pure laboratory substances generally give scores over 750 hit quality; as a result, we have used this score as a 
cut-off or threshold, although some may regard it as conservative, to evaluate the results. However, there 
may be other critical compounds at low levels that the IR technique cannot detect. For this reason, 
experienced chemists and clinicians are important in on-site interpretation and explanation of the results to 
patrons and for post site analysis.  It also highlights that printing out results and providing them to patrons is 
not a recommended approach. 
Analysis found that 46% of the chemicals identified as the top compound met the cut-off and are likely of 
reasonably high purity. Of these, 32 were identified as MDMA, three were a filler or cutting agent, one was 
cocaine, one ketamine, one a cathinone drug (N-ethylpentylone) and one caffeine.  
There were five instances where the second ranked compound had a hit quality score above the cut-off 
(>750). In each case this second match identified the same compound indicating that the libraries contained 
several different spectra for the same substance.  There were four instances where the second and third 
ranked compounds had hit quality scores above the cut-off (>750). Again, these matches identified the same 
compound. There was no case of multiple hit quality scores above cut-off (>750) that identified different 
compounds.   
For 53% of samples tested, none of the hit quality scores were above the threshold. This increased the 
uncertainty surrounding compound identification. This could arise due to the sample being an impure 
mixture of more than one compound, or due to the major compound not being included in the spectra 
libraries. Although hardware limitations prevented the use of mixture analysis or spectrum subtraction and 
re-matching on the day of the pilot, such an approach could be used in future to more closely evaluate 
sample composition where hit quality scores are low. An example of this approach is given above for 
GTM001. In this case the highest hit quality score was only 359 and identified MDMA as the major 
component (figures 5, and 6). Later mixture analysis conducted after the pilot identified dimethyl sulfone, a 
common cutting or filling agent, as the second component (figures 7 and 8).  
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PATRON DATA 
Patron data comes from two stages of the process – stage 2 which is the pre-test data collection and stage 4 
which is the post-test data collection and counselling.  Through the unique identifier these are linked to the 
chemical test results of the drugs patrons brought for testing. Table 3 shows the numbers who participated in 
each stage. As mentioned at the start of the pilot two people came as a group and both were interviewed but 
only one presented a drug for testing.  An inspection of their responses found the first patron with the 
substance said they had used drugs previously while the second patron said this was their first time. The first 
patron said they thought the substance was MDMA and did not respond to the question on whether they 
were surprised by the testing results which found MDMA as a possible component with low hit quality score; 
the second patron also indicated they thought the drugs were MDMA and indicated they were very surprised 
by the results. Both said they had secured the drugs online.  For the data analysis undertaken for this 
operational review the second patron has been excluded resulting in 83 patrons for the pre-test data. In 
terms of the drug tests two patrons did not provide sufficient quantities for analysis and there were two 
orphan samples. Post-test 74 patrons completed one or more of the post-test collection questions. 
Table 3: Number who participated 
 Yes 
Pre-test data collection 83 
Drug tests 83 
Post-test collection 74 
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
PATRON GENERAL PROFILE 
In terms of gender one-third indicated they were female (31%), two-thirds male (67%).  One patron did not 
want to answer and none indicated non-binary or a different identity. The age range was from 15 to 47 years; 
the mean age was 23 years with 45% of patrons aged 20 or younger.  
Figure 16: Age distribution (n=82) 
 
 
Ninety-three percent reported this was not the first time they had used illegal drugs. When asked how they 
got these drugs the majority reported from their friends (55%), followed by their dealer (28%). One patron 
did not answer the question and seven percent said they had found them. Of those who had found them, all 
had used before.  
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Postcode data was collected from each patron. All of the postcodes except for one from Victoria were located 
in the ACT (52%) and NSW (47%).  The largest postcode cluster (2617, n=10) effectively covers the Belconnen 
area where the festival was taking place but there were also smaller clusters across north Canberra in 2602, 
2615 and 2913. There was no difference between males and females as to whether they came from Canberra 
or NSW. However, those aged over 20 years were more likely to have come from NSW (60% vs 32%) while 
those 20 years or younger were more likely to provide an ACT postcode (68% vs 40%). 
Those aged over 20 years were slightly more likely to have sourced from a dealer (34% vs 22%) while younger 
patrons were more likely to say from friends (62% vs 50%). Females were more likely to report that their 
source was a dealer (34% vs 25%), however the same percentage of males and females reported obtaining 
from friends (54%). A small percentage of males (5%) and females (4%) said they sourced their drugs online.  
Although small, online purchasing is growing and MDMA is known to be one of the most popular drugs 
purchased through on-line anonymised dark net markets (Mounteney et al., 2016). 
Sixty-six percent reported that they knew of others using the same substance. Females were marginally more 
likely to say they knew of others using the same substance (68% vs 65%) and those aged over 20 years were 
somewhat more likely to say they knew of others using the same substance (70% vs 61%). 
COMPOUNDS DETECTED BY CHEMICAL ANALYSIS 
Table 4 shows the compounds detected as the top compound by their common terminology for all the 
patrons and then restricted to of the top two quartiles >500 and >750. As there are no agreed standards for 
cut-offs either in Australia or overseas we have elected to use a conservative threshold of >750. The largest 
compound detected regardless of cut-off is MDMA.  The total sample data indicates that the drugs being 
taken by patrons are of variable quality. Only 39 substances tested were qualitatively assessed as likely of 
reasonably high purity (>750), while a further 27 were tentatively identified and qualitatively assessed as 
likely of low purity (501-750). Of the latter group this was substantially comprised of filler or cutting agent.  
This is consistent with international findings (see Mounteney, 2018). TheLoop in the UK has also reported 
‘substitutes included ground up anti-malarial tables, household cleaner, paracetamol and concrete’ 
(https://www.theindustryobserver.com.au/study-finds/).   
Table 4: Chemicals detected for different hit quality levels 
Common name Total sample - no 
cutoff (n=83) 
Cutoff at 500 
(n=66) 
Cuttoff at 750 
(n=39) 
 number percent number percent number Percent 
MDA 1 1 1 2   
MDEA 1 1     
MDMA 42 51 38 58 32 82 
Antihistamine 1 1 1 2   
Caffeine 3 4 3 5 1 3 
Cathinone drug 1 1 1 2 1 3 
Cocaine 2 2 2 3 1  
Dietary supplement 1 1     
Fibre 3 4 3 5   
Filler or cutting agent 17 20 15 23 3 8 
Foodstuff 3 4     
General chemical 2 2     
Ketamine 1 1 1 2 1 3 
Oil 1 1     
Opium 2 2 1 2   
Protein 1 1     
Toothpaste 1 1     
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
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Depending on what drug manufacturers put into the substances this could either be highly dangerous 
(Project Know, 2018) or benign. A breakdown of the filler or cutting agent in the top two quartiles indicated 
that 13 of the compounds were lactose, 1 was MYO-INOSITOL and 1 was sucrose.  
In one case N-Ethylpentylone was detected with a hit level of 919.  This is a dangerous drug that has recently 
emerged and has been responsible for mass casualty overdoses in New Zealand (Thomas, 2018) and more 
recently, deaths (Atherton, Dye, and Beck, 2019).  Our clinician was not aware of any overdoses in the ACT 
involving this drug to date although law enforcement has subsequently confirmed that they have detected 
the drug in samples they have tested in seizures.  
The user profile was male and aged over 36 years who purchased from their dealer and had used before.  
However, they thought the substance was “meth” as that is what the dealer had told them. On learning of 
the contents they were somewhat surprised, and seemed undecided about their intended actions. They 
advised the chemist and clinician that they were going to discard it, but then indicated to the AOD worker 
that they would not discard in the amnesty bin provided in the tent but indicated that they would use less of 
the drugs. They reported they did not know of anyone else using the drug. 
A second case study was indole 3-acetamide as the first compound in one case with low hit quality of 275. On 
the night the clinician’s judgement was this was ‘suspicious’ as it is not one of the commonly occurring 
fillers/congeners and could potentially indicate one or other of the indole family of drugs that includes 
dimethyltryptamine (DMT). As a result, a red flag was raised as this was deemed the safest thing to do in the 
absence of a clear compound identification. It also highlights why the chemical testing and the clinician’s 
assessment are complementary. 
The UK pill testing group The Loop, advised they also undertake reagent testing on-site when the IR detects 
substances like “parexyl” which is classified as tooth paste. This can be a false positive which is triggered by a 
common ecstasy excipient.   It is also the case that “rayon” and “cotton fibre” can also be covering up 
something else.  It would be advisable for future testing that reagent testing be part of the chemical testing 
process. 
There were significant differences between those deemed to be above and below the threshold (>750) in 
terms of the form the drugs were presented in. Of the 41 capsules, 61% were above the threshold (that is 
reasonably high quality), of the powder form 50% were above the threshold. This compared to only 16% of 
tablets being above the threshold. Of the six presented in crystal form 83% were above the threshold.  
Of the MDMA samples above the threshold, 72% were capsules, 13% crystal, nine percent were in tablet form 
and six percent came as powder. Both the cocaine and ketamine samples above threshold were in powder 
form.  
WHAT PATRONS EXPECTED 
Patrons were asked what they thought the substances they had brought in for testing were. Table 5 shows 
that eighty-three percent said MDMA, four percent said cocaine, and two percent ketamine. In regard to how 
people obtained their drugs, friends and dealers were the most likely supplier of drugs. However, the number 
of patrons that reported their source of information about exactly what they were about to consumed was 
reversed with more saying that the dealer was more likely to have provided them with the information than 
their friends. This difference may be a wording issue related to the question asked and/or refers to people 
sourcing their information from friends who had told them what information the dealer had provided (and 
therefore was viewed as the source of information); online probably includes the instances where people 
check whether their substance matches on-line information. 
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Table 5: Drug patron expectations and supply 
 Number Percent 
Expectation of drug type (n=83)   
MDMA 70 84 
Cocaine 3 4 
Ketamine 2 2 
Endone 1 1 
Meth 1 1 
PMA 1 1 
Unknown 5 6 
Where they got drugs (n=82)   
Dealer 23 28 
Friends/acquaintance 47 57 
Found it 6 7 
Online 4 5 
Other (a) 2 2 
Their source of information (n=82)   
Already tried 6 7 
Dealer said 51 61 
Friends said 13 16 
Online 6 7 
Found it 6 7 
(a) Other includes prescribed and rather not say  
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
CONCORDANCE BETWEEN EXPECTATION AND TESTING 
Table 6 shows concordance between the patron’s expectation and what was actually found from the IR 
testing using the >750 cut-off. The analysis of concordance using Kappa found only 43% agreement which is 
fair to moderate concordance indicating that patron’s knowledge of what they are taking is often not well 
founded. Even if we conduct the analysis with no cut-off for the IR detection the agreement rating only rises 
to 62%. This is lower than that reported by The Loop which reports a concordance of 80% (TripleJ Hack, 
2017). This confirms that Australian MDMA has higher rates of substitution or impurities in the tablets sold 
on the unregulated market. 
Of the 81% who thought they were consuming MDMA, 45% (n=31) did have MDMA identified as the major 
component while for 54% no compounds were detected above the cut-off threshold. None of the three 
people who thought they were consuming cocaine were found to have cocaine above threshold while one of 
the two people who thought they had ketamine were found with ketamine in the drug sample. Of the eight 
people who reported a range of other drugs they were expecting half did not have compounds found above 
the threshold.  
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Table 6: Concordance between expectations and IR detection (n=81) 
 Expected drug 
 MDMA (n=69) Cocaine (n=3) Ketamine (n=2) Other (n=7) 
 N % N % N % N % 
IR detection – above 750 cutoff         
MDMA 31 45 0 0 0 0 0 0 
Cocaine 0 0 0 0 0 0 0 0 
Ketamine 0 0 0 0 1 100 0 0 
Other 2 3 0 0 0 0 3 43 
Nothing detected above cut-off 36 52 3 100 1 50 4 57 
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
Of the two who thought their drugs were ketamine in one case, a female, the testing found ketamine (905).  
In the other case antihistamine was found as the top compound (745) but ketamine was found as the second 
best match but at a much lower hit quality level (206). The male who brought in the substance was very 
surprised by the results. Of the cocaine, one was of high purity (926) but was an orphan sample; the other 
sample was moderate (689). For the latter sample, the patron (gender was not provided) was expecting it to 
be cocaine.  
Those with high concordance (that is their expectation is confirmed by the drug testing) are significantly more 
likely to be males and aged 20 years or younger. Those who reported they sourced the drugs from a friend 
rather than the dealer were somewhat more likely to have high concordance (47% vs 39%).  Of the five 
people who said they had not tried illicit drugs before only one had a concordant result.  
Forty percent of those who provided information post the testing of the drugs indicated they were not 
surprised by the results of the chemical tests while 19 percent were somewhat surprised and 41 percent 
reported being very surprised.  Table 7 confirms what we would expect – those whose expectations were 
confirmed by the testing were more likely to not be surprised while the opposite is the case for those whose 
expectations were not confirmed. However even those with high concordance expressed surprised with the 
results (28%). 
Table 7: Response to results of testing by concordance (n=73) 
 Concordance 
 No Yes 
 N % N % 
Not at all surprised 13 32 16 50 
Somewhat surprised 7 17 7 22 
Very surprised 21 51 9 28 
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
INTENDED BEHAVIOUR 
After receiving the information on the chemical testing of their drugs 58 percent indicated they intended to 
use the drugs as planned. Twelve percent said they would use less, five percent said they would not use this 
drug but another drug, seven percent were undecided while 18 percent said they would not use illicit drugs.  
Eight percent (n=6) reported that they would discard the drugs, 81 percent (n=59) said they would not use 
the amnesty bin while 11 percent (n=8) were not sure. From the observations on the night five people were 
observed using the amnesty bins.  Given the constraints already described earlier in the report the eight who 
were unsure could be converted into ‘observed discards’ with more appropriate arrangements. If this was the 
case it would result in 19 percent ‘discarding’ which would be consistent with The Loop which reports that 
around 20% bin their drugs (http://www.abc.net.au/triplej/programs/hack/how-pill-testing-works-in-the-
united-kingdom/9146380).  
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There is a significant difference in the reported intended behaviour between those whose chemical tests 
showed reasonably high purity as opposed to those with tests indicating low purity (see Table 8).  Those with 
low purity test results were more likely to be undecided or intended not to use or were more likely to say 
they would discard their drugs. However, even those with a high purity report said that they would modify 
their behaviour with 12 percent saying they don’t intend to use and 18 percent report they will use less. 
Table 8: Intended behaviour (n=74) 
 Low purity High purity 
 N % N % 
Future use     
Undecided 5 13 0 0 
No future use 9 23 4 12 
Use less 3 8 6 18 
Not use this, but use other drug 3 8 1 3 
Same use 20 50 22 69 
Discard     
Yes 5 12 1 3 
Unsure 7 17 1 3 
No 29 71 29 94 
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
A logistic model where the dependent variable was some change versus no change was estimated. Table 9 
indicates that there are three significant predictors.  Females and those who were surprised by the results are 
significantly more likely to report that they will change their behaviour. Those who sourced from a dealer 
were less likely to indicate that would change their drug use behaviour. When controlling for these range of 
factors the purity of the substance detected is not a significant predictor of whether people intend to change 
or not. 
Table 9: Predicting intended change in behaviour (n=72) 
 
Odds 
Ratio Std. Err. z P>z 
[95% 
Conf. Interval] 
Female 3.23 1.86 2.04 0.04 1.05 9.96 
Aged over 20 years 0.99 0.58 -0.01 0.99 0.32 3.09 
Sourced from friend 0.51 0.39 -0.88 0.38 0.11 2.30 
Sourced from dealer 0.23 0.21 -1.66 0.10 0.04 1.31 
Surprised by results 2.63 1.52 1.68 0.09 0.85 8.16 
ACT postcode 0.44 0.25 -1.43 0.15 0.14 1.36 
High purity 0.52 0.29 -1.19 0.24 0.17 1.54 
Constant 3.23 1.86 2.04 0.04 1.05 9.96 
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
DISSEMINATION 
Sixty-six percent reported that they knew of others using the same drugs. When asked if they would tell them 
about the results 90 percent said yes. This is a very high number and represents a number of other people 
being informed of the testing results and the dissemination of information well beyond those that presented 
to the service. 
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If 44 out of 83 patrons tested, on average, tell three other people dissemination increases to approximately 
another 132 people who are provided with information of both the tests but also relevant AOD messages. If 
these people in turn speak with other people, the reach of the information becomes very high and potentially 
very quickly. 
There is also research available that demonstrates that young people are influenced by other young people; 
and these are also more likely to be trusting relationships, especially when compared to the messages and 
other information received from government and other public campaigns. Relaying AOD messages through 
peers who have been given credible advice may assist in reducing harmful drug use amongst a population 
who do not traditionally access drug and alcohol services. 
SERVICE RATINGS 
Eighty-three percent said they rated the service as very good, with 13 percent reporting it was good. Four 
percent said it was reasonable.  Nobody indicated the service was poor or very poor. Patrons were asked to 
comment on how the service might be improved. Table 10 indicated the issues raised by patrons.  These 
issues accord with the earlier discussion about how to improve the process of on-site service delivery. 
Table 10: Service improvements by patrons (n=74) 
 N % 
More testing facilities 8 11 
More space 14 19 
Better signage 21 28 
Reduced security 7 9 
Reduce waiting queues 11 14 
More staff 3 4 
Source: HRA STA-SAFE, 2018, Merged ACT GTM file, N=86 
COSTS OF SERVICE DELIVERY 
The pilot was undertaken by a consortium of people and organisations, all of whom provided their services pro 
bono. This is not a long-term or sustainable model. In the UK in 2016 The Loop was established as a foundation 
that relies on pro bono support from key people such as medical practitioners, chemists and entertainers while 
working with local police forces, public health officials and authorities. The organisation has an active strategy 
to secure donors who provide funding for long-term sustainable service delivery. The Loop uses the IR 
spectroscopy which was also employed at the ACT pilot. Depending on the substances and results of testing, 
The Loop may undertake further work on the samples (see https://wearetheloop.org/equipment/).  
There is a network of European Drug Checking (The Trans-European Drug Information or TEDI) groups who 
share expertise and data that helps to build the spectra libraries along with collecting other evidence. A key 
practical benefit of membership is access to immediate information on the emergence of novel psychoactive 
substances. The Loop reports that ‘at least one new psychoactive substance on the market was being 
reported every week’ through the network (https://wearetheloop.org/collaborators/ ).  
Table 11 provides an estimate of the costs of providing the pill testing service on the night. These represent 
the approximate minimal recurrent costs of service delivery which was $34,000, although it should be noted 
that $5,000 of this amount was estimated for payments to the festival for paramedic and security services 
contributions. 
While this may seem like a substantial amount of money, it represents roughly an order of magnitude less 
than the money invested annually in the sniffer dog program in NSW (TripleJ Hack, 2016). In other words, for 
the same investment 10 separate pill testing programs could be funded to provide an opportunity to 
positively engage with young drug consumers and collect meaningful, actionable, de-identified intelligence on 
the illicit drugs market - neither of which sniffer dogs can do. 
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Table 11: Estimated costs of delivery of on-site pill testing 
Item Budget Details GTM Pilot Funding Source 
Spectrometer (inc. software 
updates) Confidential Non-recurrent payment 
STA-SAFE organised equipment 
to be loaned 
Confirmatory Testing Equipment 0 Non-recurrent payment Not available 
Furniture, amnesty bin etc. 500  STA-SAFE Payment 
Stationery 500   STA-SAFE Payment 
Educational Material 500   STA-SAFE Payment 
Clinical Director x 1 2,000 Medical Practitioner STA-SAFE (Pro-bono contribution)  
Analysts x 3 3,000 
Chemists trained in use of 
Pill Testing Equipment STA-SAFE (Pro-bono contribution)  
Peer Counsellors x 5 5,000 
Trained in Pill Testing and 
Festival Work STA-SAFE (Pro-bono contribution)  
Review x 2 1,500 Operational review STA-SAFE (Pro-bono contribution)  
Security Staff 2,500  
Reimbursement to Festival 
Promoters 
Paramedic Staff 2,500  
Reimbursement to Festival 
Promoters 
Interstate travel 6,000   STA-SAFE Payment 
Accommodation  1,500   STA-SAFE Payment 
Travel Allowance 1,500   STA-SAFE Payment 
Disposal Fees 500   STA-SAFE Payment 
Promotion  1,500   STA-SAFE (Pro-bono contribution)  
Report Preparation 2,500   STA-SAFE (Pro-bono contribution)  
International Collaboration 0   Not Available 
Insurances 2,500   STA-SAFE Payment 
Total Expenditure 34,000  Recurrent budget = 34,000 
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CONCLUSION 
The purpose of the pilot was to test a number of aspects of a pill testing service at a popular Australian music 
festival. The most critical question was whether it was possible to actually deliver an on-site “front-of-house” 
chemical testing service at a festival in Australia. There is no question that this was achieved without any 
major or minor incident. Even though no information about the availability of the service was provided to 
patrons at the festival, 129 people located the facility and were assessed as eligible to access the pill testing 
site (two additional patrons were turned away). Patrons were advised of the conditions of entry and were 
willing to sign the waiver form. 
FTIR testing was carried out and subsequent analysis found a range of substances ranging from lactose to 
high purity MDMA, cocaine and ketamine. The testing also confirmed that there is significant variability in the 
purity of illicit drugs being consumed. Importantly, one dangerous substance that has led to hospitalisations 
in New Zealand and deaths in the US, was confirmed amongst samples tested on-site. Sixty-one per cent of 
patrons were surprised by the results of testing. Substances presented in tablet form were significantly more 
likely to be of lower purity than other forms; high purity MDMA was most likely to come in capsules. 
Although there was security present at the entrance to the service, law enforcement members kept a 
respectable distance while still doing their routine work. They inspected the service to ensure that all agreed 
protocols were in place and appropriately implemented. This is a standard operating procedure adopted by 
patrols near needle and syringe programs at fixed sites in public and around health services on-site at events 
where drug-related presentations do reasonably occur.  
Three quarters of those who brought drugs for testing received some AOD brief intervention counselling. 
Forty-two per cent reported that their drug consumption behaviour would change as a result of the testing 
and 18 per cent indicated that they would either discard the drugs in the amnesty bins provided or were 
uncertain as to what they would do as a result of the information provided by the service. 
Good practice guidelines for pill testing exist in Europe; these cover the broad principles for the 
establishment, delivery and evaluation of services for a range of “nightlife” interventions (Ventura et al, 
http://newip.safernightlife.org/pdfs/standards/NEWIP_D_standards-final_20.12-A4.pdf ). The STA-SAFE team 
followed these as closely as the operational constraints in Australia would allow. The pilot highlighted a 
number of operational factors that must be addressed to improve the effectiveness and efficiency of the 
service. These factors have been highlighted throughout this report. It is clear that Australian guidelines, 
tailored to the local socio-political context and designed to be implemented by Australian teams, need to be 
developed as a matter of priority. 
Another key issue is further technology refinements that need to be implemented to compliment the FTIR 
testing. Given the high number of cutting agents identified in our tests, reagent testing or complementary 
testing methodologies such as mass spectrometry should be included in future tests. This will assist in 
determining if cutting agents are masking other chemicals.  
The current science around the testing of pills is at the same embryonic stage as waste water analysis over a 
decade ago. Over the past ten years, with the continental Europeans leading the way, ‘a best-practice 
protocol with regard to sampling, sample handling, chemical analysis, back-calculation and data reporting’ 
(Castiglioni, 2016:7) has been developed for waste water testing.  
It is important to realise that the two approaches serve different purposes but have the potential to provide 
complementary data. Pill testing is a point of service which tests the drugs before they are consumed and, 
critically, provides immediate information to consumers about their individual drug, while waste water 
analysis tests for metabolites that can’t be linked back to individuals and potentially provides population 
rates for drug consumption. Waste water testing at festivals may reflect the types and levels of drugs 
consumed days prior to the festival; there is limited capacity to report “dangerous” drugs directly linked to 
the festival and no capacity to alert individuals about the substances they are proposing to consume. It is also 
not possible to discern where the substances may have originated via signature profiling nor to obtain data 
on the major compounds detected in a single pill. However, Castiglioni (2016: 12) has noted that in terms of 
monitoring drug use interesting possibilities emerge if different forms of data collection were co-ordinated 
and assessed –in this case it might involve a general survey of festival patrons, pill testing and waste water  
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analysis. Pill testing provides an opportunity for Australia to participate in the development of science in this 
field, to inform the evidence base for future policy and practice and to provide a direct, immediate harm 
reduction intervention that is already widespread across Europe and in the past year has been implemented 
at some festivals in England, Wales and North America. 
Waste water testing is unlikely to provide cutting-edge intelligence on rare substances like ethylpentylone or 
substances that are emerging and yet to be characterised. On the other hand, pill testing offers the 
opportunity to provide such “just in time” intelligence to both police and health services. However, a model 
that only provides “back-of-house” testing cannot communicate directly to the consumer the specific 
intelligence on the particular substance they use, nor does it deliver robust medical advice and engagement 
with peer-based counsellors about the evidence-based risks of drug consumption.  
Young people take risks and festivals are an environment in which they are surrounded by peers; the research 
shows both that the young take more risks and that they are more likely to be influenced by peers. 
Establishing a “front-of-house” pill testing model – as was the case with this pilot – is clearly possible and 
practicable and offers peer-based brief interventions, counselling and referrals as a central part of a holistic 
approach that encompasses harm reduction with a pragmatic focus on both demand and supply reduction. 
Pill testing as a harm reduction service at the ACT GTM can be described as an overwhelming success. 
The pilot demonstrated that such an intervention is possible and that people are willing to use the service, 
despite the limitations arising from the tight timelines, inauspicious physical infrastructure and the lack of 
dissemination strategies on-site during the festival. 
The development of a uniquely Australian pill testing service model that involves peers, health professionals 
and law enforcement officials working together to reduce harm amongst drug users needs to be prioritised 
and supported by all Australian governments. 
To conclude this report and illustrate the success of the ACT pill testing pilot some of the commentary 
provided by community leaders in the ACT after the festival is noted below. 
 
ACT Health Minister Meegan Fitzharris  
The trial was a success and had shown there was a demand for the service. This will assist to better 
understand how pill testing may help reduce the harms of illicit drug use at festivals and will inform next steps 
and future drug policy. As the first trial to be conducted in Australia, I know that other jurisdictions will be 
looking on with interest to see the results of the evaluation. We look forward to releasing the evaluation once 
complete 
ACT Chief Police Officer Justine Saunders 
Our intention was to focus our efforts on those who were trafficking and selling drugs, focusing on the 
criminality of drugs but allowing the pill testing to occur in a safe way. The day overall was a great success. 
We are not in the business of targeting people who abuse drugs. We’re very focused on criminality, focused on 
the selling and trafficking of drugs at these events. 
ACT Chief Health Officer Dr Paul Kelly 
If we continue to do what we have been doing for the past 20 or 30 years in relation to drug policy, we will 
continue to get the issues that we face at festivals and other places every weekend and day in day out in 
Australia of kids putting themselves in harm. At least with pill testing, they have some information to guide 
their behaviour and we did see yesterday people changing their behavioural choices on the basis of the 
information they were given. The trial was a success and the lessons learned would be really valuable for the 
ACT and other jurisdictions around Australia. 
ACT Ambulance Commander Toby Keen 
We didn’t see anyone who'd been to pill-testing. It's worthwhile noting the people we transported for acute 
intoxication hadn't been to pill-testing which I think is actually a good success marker for the pill-testing. 
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APPENDIX 1: SAFETY GUIDELINES 
All patrons are required to sign a waiver before testing is possible (Note: you must be observed as having the 
capacity to sign a waiver; it will be destroyed after the event) 
To ensure the confidentiality of the service, photography of any kind is strictly prohibited - all patrons must 
submit their phones to staff prior to entering the tent (We will take reasonable steps to keep your property 
safe, but we do not accept liability for any property that is lost, stolen, or damaged in the process) 
This is an anonymous service - we will collect de-identified information for evaluation purposes only 
If a patron enters the tent with a large amount of a substance (deemed a commercial quantity), they will be 
refused service 
If a patron is showing signs of illness or intoxication, they will be referred to on-site health or welfare services 
Any anti-social behaviour will be reported to on-site security and/or police; this includes attempting to take 
photographs, aggression, being in possession of illicit substances in public viewing, or possessing large 
quantities 
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APPENDIX 2: ELIGIBILITY SCREENING FORM 
Harm Reduction Australia (HRA) 
Initial assessment for eligibility to access testing facility 
If intoxicated or engages in anti-social behaviour they are not eligible to participate. 
If eligible refer to drug testing area. 
Record time and tick appropriate box for EVERY person who presents 
 
Record 
time  
Assessed 
Eligible to  
refer to 
drug 
testing 
area 
NOT ELIGIBLE – TICK APPROPRIATE BOX/ RECORD REASON 
Too 
young 
Intoxicated 
refer Red 
Frogs 
Antisocial behaviour –note 
behaviour and action taken 
eg. aggression, requested 
security 
 
Other -- record reason 
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APPENDIX 3: WAIVER FORM 
Patron Pill Testing Liability Waiver 
To be signed by any patron before commencing pill testing. 
 
I, the person signing this document (I/me), agree that in consideration of receipt of  the pill 
testing service carried out by Harm Reduction Australia (HRA) at the 'Groovin the Moo' festival 
(Festival) on 29 April 2018 at The University of Canberra (Services), to release and discharge HRA, its 
employees, directors, contractors and volunteers and any other person connected with the 
provisions of the Services from any liability for personal injury or death suffered by me arising 
or connected in any way from the Services. 
 
By signing I confirm having read and understood the contents of this waiver. 
 
NAM E: ........ .................................................  SIGN HERE......... ......... .............. .DATE: ............... 
 
 
No test results regardless of findings: 
 
1) Provides evidence of purity 
     (Drugs are almost always adulterated) 
 
2) Provides evidence of safety 
  (no drug is completely safe, even if it is pure) 
 
3) Provides evidence of dose 
  (you never know how weak or strong the effects will be) 
 
4) Provides information about how you will respond to the product being tested, today. 
 
 
I understand that the advice provided does not constitute any recommendation to consume drugs, and has been 
provided for the purposes of preventing drug related harm. 
All drug use carries with it an inherent risk. 
The only way to guarantee, 100%, that you are not harmed by consuming drugs is not to consume drugs. 
 
 
 
Sample Number: ......... ............... Initial: ...................... 
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APPENDIX 4: PRE-TESTING DATA COLLECTION SHEET 
Harm Reduction Australia (HRA) 
Pre-result data collection instrument 
As this is a trial of drug testing HRA is collecting some basic data to help inform the government as to whether 
the service is worthwhile and should continue. None of the information you provide will be linked to you and 
it will only be used to develop aggregated statistics to inform future drug testing services. We are using a 
unique id number to anonymously link the testing results. If you don’t want to answer the questions you 
don’t have to; or if there is a particular question you don’t want to answer that is okay.  You will still be able 
to access the pill testing facilities.   
Would you answer some questions?  
Tick box: Patron agrees to proceed  
Q1. We are interested in knowing what you think the drugs you are getting tested are? Record the name(s): 
 
 
 
Q2. What makes you think that? Tick the most appropriate box 
  Already tried it  That ͛is what I was told by the dealer  What my friend(s) said it was  Other and 
record        
Q3. Is this the first time you have ever used illegal drugs? Tick box 
 Yes |  No  
Q4. Would you tell us how you got these drugs? Tick the most appropriate box  
 Dealer  Friend  Relative  Workmate  Acquaintance  Gift  Online  Don't know  Rather not 
answer 
Q5. Can you tell us your gender? Tick the most appropriate box 
 Male  Female  Non-binary  Different identity  Rather not answer  
Q7. What year were you born in? Record year in box 
Q8. Finally, can we ask for your postcode? Record postcode in box 
 
Many thanks. We would like to ask a few more questions after you get your results if that is okay.   
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APPENDIX 5: POST-TESTING DATA COLLECTION SHEET 
Harm Reduction Australia (HRA)  
Post testing data collection instrument 
We would like to ask a few questions to get some feedback on the service. 
Tick box: patron agrees       
Q1. Were you surprised by the test results?  Tick the most appropriate box 
 Not at all  Somewhat  Very surprised  
Q2. Do you know others using the same substance? Tick box 
 Yes |  No 
Q3. Will you tell them the results? Tick box 
 Yes |  No 
Q4. Has the testing changed your mind as to whether you intend to use these drugs at the festival? Tick the 
most appropriate box 
 No, I intend to still use it as initially intended  Yes, but I will use less  No, I will use other illicit drugs 
instead  Not sure   Will not be using any illicit drugs 
Q5. Will you discard your drugs in the amnesty bin? Tick box 
 Yes |  No|  Not sure 
Q6. How would you rate the service? Tick the most appropriate box 
 Very poor  Poor  Reasonable  Good   Very good  
Q7. How could we improve the service? Record suggestions: 
 
 
 
 
Q8. Is there any other feedback you would like to give us? Record responses: 
 
 
 
 
Thanks very much for your time.   
Write id number here 
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